Clinical trial
Targeting ADAM17 Activity for Correction of Vascular Insulin Resistance in Type 2 Diabetes
NCT04557228 is registered in ClinicalTrials.gov with University of Missouri-Columbia as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Targeting ADAM17 Activity for Correction of Vascular Insulin Resistance in Type 2 Diabetes
- Lead sponsor
- University of Missouri-Columbia
- Phase
- Not applicable
- Overall status
- Completed
- Start date
- March 1, 2023
- Completion date
- November 1, 2025
- Enrollment
- 36 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.